Medigene 

Medigene AG is a biotechnology firm dedicated to advancing T-cell immunotherapies for the treatment of cancer. The company's core therapeutic focus involves the development of personalized T-cell-based treatments, specifically T-cell receptor (TCR)-modified T cells, aimed at addressing significant unmet medical needs. These innovative therapies are currently in clinical development. Beyond its primary T-cell immunotherapy work, Medigene is also engaged in researching and developing dendritic cell vaccines and T-cell-specific monoclonal antibodies. Additionally, the company is involved in the development and commercialization of RhuDex, a compound for use in hepatology and gastroenterology indications. Medigene AG has formed a strategic partnership with 2seventy bio, Inc. for the collaborative advancement of T-cell receptors. The company also maintains research collaboration agreements with the Université de Montréal and Cytovant Sciences Co. Ltd., focusing on novel cancer antigens for immunotherapy applications. With operations spanning Europe, the United States, Asia, and other international markets, Medigene AG was founded in 1994 and is headquartered in Munich, Germany.